Charlotta Pisinger

Prof. Dr. Charlotta Pisinger

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Preventive Medicine
Verified
Journal Article
Open access
CPCharlotta Pisinger
Charlotta Pisinger
MDMartin Døssing
Martin Døssing
To provide a systematic review of the existing literature on health consequences of vaporing of electronic cigarettes (ECs). Search in: PubMed, EMBASE and CINAHL. Original publications describing a health-related topic, published before 14 August 2014. PRISMA recommendations were followed. We identified 1101 studies; 271 relevant after screening; 94 eligible. We included 76 studies investigating content of fluid/vapor of ECs, reports on adverse events and human and animal experimental studies. Serious methodological problems were identified. In 34% of the articles the authors had a conflict of interest. Studies found fine/ultrafine particles, harmful metals, carcinogenic tobacco-specific nitrosamines, volatile organic compounds, carcinogenic carbonyls (some in high but most in low/trace concentrations), cytotoxicity and changed gene expression. Of special concern are compounds not found in conventional cigarettes, e.g. propylene glycol. Experimental studies found increased airway resistance after short-term exposure. Reports on short-term adverse events were often flawed by selection bias. Due to many methodological problems, severe conflicts of interest, the relatively few and often small studies, the inconsistencies and contradictions in results, and the lack of long-term follow-up no firm conclusions can be drawn on the safety of ECs. However, they can hardly be considered harmless.

22 January 2019 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
THThomas Huneck Haupt
Thomas Huneck Haupt
LRLine Jee Hartmann Rasmussen
Line Jee Hartmann Rasmussen
TKThomas Kallemose
Thomas Kallemose
SLSteen Ladelund
Steen Ladelund
OAOve Andersen
Ove Andersen
JEjesper eugen-olsen
jesper eugen-olsen
The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is a strong predictor of disease development and premature mortality in the general population. Unhealthy lifestyle habits such as smoking or unhealthy eating is known to elevate the suPAR level. We aimed to investigate whether change in lifestyle habits impact on the suPAR level, and whether the resultant levels are associated with mortality. Paired suPAR measurements from baseline- and the 5-year visit of the population-based Inter99 study were compared with the habits of diet, smoking, alcohol consumption, and physical activity. Paired suPAR measurements for 3225 individuals were analyzed by linear regression, adjusted for demographics and lifestyle habits. Compared to individuals with a healthy lifestyle, an unhealthy diet, low physical activity, and daily smoking were associated with a 5.9, 12.8, and 17.6% higher 5-year suPAR, respectively. During 6.1 years of follow-up after the 5-year visit, 1.6% of those with a low suPAR (mean 2.93 ng/ml) died compared with 3.8% of individuals with a high suPAR (mean 4.73 ng/ml), P < 0.001. In Cox regression analysis, adjusted for demographics and lifestyle, the hazard ratio for mortality per 5-year suPAR doubling was 2.03 (95% CI: 1.22–3.37). Lifestyle has a considerable impact on suPAR levels; the combination of unhealthy habits was associated with 44% higher 5-year suPAR values and the 5-year suPAR was a strong predictor of mortality. We propose suPAR as a candidate biomarker for lifestyle changes as well as the subsequent risk of mortality.

1 June 2015 in Health Policy
Verified
Journal Article
Closed access
MBMalene Bødker
Malene Bødker
CPCharlotta Pisinger
Charlotta Pisinger
UTUlla Toft
Ulla Toft
TJTorben Meinertz Joergensen
Torben Meinertz Joergensen

1 October 2019 in Preventive Medicine
Verified
Journal Article
Closed access
CKCiaran D. Kennedy
Ciaran D. Kennedy
MSMay C.I. van Schalkwyk
May C.I. van Schalkwyk
MMMartin McKee
Martin McKee
CPCharlotta Pisinger
Charlotta Pisinger

1 February 2019 in Preventive Medicine
Verified
Journal Article
Closed access
CPCharlotta Pisinger
Charlotta Pisinger
NGNina Godtfredsen
Nina Godtfredsen
ABAnne Mette Bender
Anne Mette Bender

CPCharlotta Pisinger
Charlotta Pisinger
SRSofie Bergman Rasmussen
Sofie Bergman Rasmussen
Background: A high prevalence of dual use of e-cigarettes and conventional cigarettes has been reported across the world. Methods: A systematic search was carried out. We included original articles on any topic relevant to health, excluding mental health, in all languages. The PRISMA guidelines were followed. Both reviewers independently screened and read all publications. We compared dual use with exclusive smoking of conventional cigarettes (ESCC). Results: Fifty-two publications (49 studies) were included. Thirteen papers/10 studies were prospective. There was great heterogeneity across studies. Many methodological weaknesses, such as inaccurate exposure measurement, lack of adjustment for former tobacco consumption, and lack of significance testing were identified. Most prospective studies found dual use to be at least as harmful as ESCC. The longest follow-up was six years. Most of the best available cross-sectional studies found dual use associated with the same and, in several studies, significantly higher risk of self-reported symptoms/disease than in ESCC. The intensity of cigarette smoking seems associated with worse health. Conclusion: Existing studies indicate that dual use is at least as, or probably even more, harmful than ESCC. Due to the predominance of cross-sectional studies and the methodological weaknesses we judged the overall certainty of the evidence as “low certainty”.